Tag Archives: Ahu Demir

Noble Financial Thinks Electrocore’s Stock is Going to Recover

In a report released today, Ahu Demir from Noble Financial reiterated a Buy rating on Electrocore (ECOR – Research Report), with a price target of $4.00. The company’s shares closed last Monday at $0.92, close to its 52-week low of

Dyadic International (DYAI) Receives a Buy from Noble Financial

In a report released today, Ahu Demir from Noble Financial reiterated a Buy rating on Dyadic International (DYAI – Research Report), with a price target of $11.00. The company’s shares closed last Monday at $6.27. According to TipRanks.com, Demir is

Noble Financial Maintains Their Buy Rating on Electrocore (ECOR)

Noble Financial analyst Ahu Demir maintained a Buy rating on Electrocore (ECOR – Research Report) today and set a price target of $4.00. The company’s shares closed last Monday at $0.45, close to its 52-week low of $0.32. According to

TherapeuticsMD (TXMD) Gets a Buy Rating from Noble Financial

In a report released yesterday, Ahu Demir from Noble Financial reiterated a Buy rating on TherapeuticsMD (TXMD – Research Report), with a price target of $13.00. The company’s shares closed last Monday at $2.31, close to its 52-week low of

Onconova Therapeutics (ONTX) Gets a Buy Rating from Noble Financial

In a report issued on October 25, Ahu Demir from Noble Financial maintained a Buy rating on Onconova Therapeutics (ONTX – Research Report), with a price target of $12.00. The company’s shares closed last Monday at $0.68, close to its

TrovaGene (TROV) Receives a Buy from Noble Financial

Noble Financial analyst Ahu Demir maintained a Buy rating on TrovaGene (TROV – Research Report) yesterday and set a price target of $23.00. The company’s shares closed last Monday at $1.34, close to its 52-week low of $1.21. According to